Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Two multidisciplinary, international conferences with a focus on the implications of new clinical findings on your daily practice.

PROSCA/BLADDR 2022

Global Congress on Prostate Cancer and Global Congress on Bladder Cancer
18–21 October 2022 | Athens, Greece

PROSCA/BLADDR 2022

Global Congress on Prostate Cancer and Global Congress on Bladder Cancer
18–21 October 2022 | Athens, Greece
Two multidisciplinary, international conferences with a focus on the implications of new clinical findings on your daily practice.
Genomic and tumor characterisation of upper tract urothelial carcinoma 4:04
Genomic and tumor characterisation of upper tract urothelial carcinoma
Eva Compérat • 19 Oct 2022
New concepts in prostate cancer pathology 3:50
New concepts in prostate cancer pathology
Eva Compérat • 19 Oct 2022
2022 WHO classification: updates in bladder cancer 4:00
2022 WHO classification: updates in bladder cancer
Eva Compérat • 19 Oct 2022
Remaining questions in mHSPC 2:27
Remaining questions in mHSPC
Silke Gillessen • 18 Oct 2022
Evolving strategies in mHSPC 4:21
Evolving strategies in mHSPC
Silke Gillessen • 18 Oct 2022
APCCC 2022: PSMA-PET, adjuvant radiotherapy vs early salvage radiotherapy 4:33
APCCC 2022: PSMA-PET, adjuvant radiotherapy vs early salvage radiotherapy
Silke Gillessen • 18 Oct 2022
Role of neoadjuvant chemotherapy in patients undergoing bladder-sparing treatments 1:45
Role of neoadjuvant chemotherapy in patients undergoing bladder-sparing treatments
Aristotelis Bamias • 19 Oct 2022
Role of systemic therapy in bladder preservation in MIBC 2:30
Role of systemic therapy in bladder preservation in MIBC
Aristotelis Bamias • 19 Oct 2022
IsoPSA: blood-based assay for improved detection of prostate cancer 2:09
IsoPSA: blood-based assay for improved detection of prostate cancer
Eric Klein • 18 Oct 2022
Polygenic risk scores for the early detection of prostate cancer 1:14
Polygenic risk scores for the early detection of prostate cancer
Eric Klein • 18 Oct 2022
Role of genomic profiling in the management of intermediate-risk prostate cancer 2:57
Role of genomic profiling in the management of intermediate-risk prostate cancer
Eric Klein • 18 Oct 2022
Highlights from PROSCA/BLADDR 2022 1:07
Highlights from PROSCA/BLADDR 2022
Aristotelis Bamias • 19 Oct 2022
Potential of platinum-free treatment approaches in patients with mUC 1:30
Potential of platinum-free treatment approaches in patients with mUC
Aristotelis Bamias • 19 Oct 2022
MCED: reducing cancer mortality 2:41
MCED: reducing cancer mortality
Eric Klein • 18 Oct 2022
Patient and physician treatment decision-making: active surveillance or intervention 2:16
Patient and physician treatment decision-making: active surveillance or intervention
Johan Stranne • 18 Oct 2022
Active surveillance or intervention in intermediate-risk prostate cancer 1:42
Active surveillance or intervention in intermediate-risk prostate cancer
Johan Stranne • 18 Oct 2022
The content of VJOncology is intended for healthcare professionals